SC 13G 1 e620156_sc13g-lp.htm THE SCHEDULE 13G

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

______________

 

SCHEDULE 13G

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

 

(Amendment No. )1

 

Lexicon Pharmaceuticals, Inc.

(Name of Issuer)

 

Common Stock, par value $0.001

(Title of Class of Securities)

 

528872302

(CUSIP Number)

 

December 11, 2020

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

   ☐  Rule 13d-1(b)

   ☒  Rule 13d-1(c)

   ☐  Rule 13d-1(d)

 

 

1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

  1  

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY 

  
         
        Biotechnology Value Fund, L.P.  
  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) ☒
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        Delaware  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         0 shares  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING        

5,791,837 

  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          0 shares  
    8   SHARED DISPOSITIVE POWER  
           
         

5,791,837 

  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
       

5,791,837

  
  10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     ☐
       
           
  11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  
         
        4.1%  
  12  

TYPE OF REPORTING PERSON*

  
         
        PN  

 

2 

 

    

  1  

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY 

  
         
       

BVF I GP LLC 

  
  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) ☒
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        Delaware  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         0 shares  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING        

5,791,837 

  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          0 shares  
    8   SHARED DISPOSITIVE POWER  
           
         

5,791,837 

  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
       

5,791,837

  
  10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     ☐
       
           
  11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  
         
        4.1%  
  12  

TYPE OF REPORTING PERSON*

  
         
        OO  

 

3 

 

 

  1  

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY 

  
         
       

Biotechnology Value Fund II, L.P.

  
  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) ☒
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        Delaware  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         0 shares  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING        

4,255,514

  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          0 shares  
    8   SHARED DISPOSITIVE POWER  
           
         

4,255,514

  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
       

4,255,514

  
  10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     ☐
       
           
  11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  
         
        3.0%  
  12  

TYPE OF REPORTING PERSON*

  
         
        PN  

 

4 

 

  

  1  

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY 

  
         
       

BVF II GP LLC

  
  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) ☒
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        Delaware  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         0 shares  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING        

4,255,514

  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          0 shares  
    8   SHARED DISPOSITIVE POWER  
           
         

4,255,514

  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
       

4,255,514

  
  10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     ☐
       
           
  11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  
         
        3.0%  
  12  

TYPE OF REPORTING PERSON*

  
         
        OO  

 

5 

 

 

  1  

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY 

  
         
       

Biotechnology Value Trading Fund OS LP 

  
  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) ☒
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
       

Cayman Islands

  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         0 shares  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING        

704,353

  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          0 shares  
    8   SHARED DISPOSITIVE POWER  
           
         

704,353

  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
       

704,353

  
  10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     ☐
       
           
  11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  
         
       

Less than 1% 

  
  12  

TYPE OF REPORTING PERSON*

  
         
        PN  

 

6 

 

  

  1  

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY 

  
         
       

BVF Partners OS Ltd. 

  
  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) ☒
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
       

Cayman Islands 

  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         0 shares  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING        

704,353

  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          0 shares  
    8   SHARED DISPOSITIVE POWER  
           
         

704,353

  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
       

704,353

  
  10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     ☐
       
           
  11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  
         
       

Less than 1% 

  
  12  

TYPE OF REPORTING PERSON*

  
         
        OO  

 

7 

 

  

  1  

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY 

  
         
       

BVF GP HOLDINGS LLC 

  
  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) ☒
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        Delaware  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         0 shares  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING        

10,047,351

  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          0 shares  
    8   SHARED DISPOSITIVE POWER  
           
         

10,047,351

  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
       

10,047,351

  
  10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     ☐
       
           
  11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  
         
        7.1%  
  12  

TYPE OF REPORTING PERSON*

  
         
        OO  

 

8 

 

  

  1  

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY 

  
         
       

BVF Partners L.P. 

  
  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) ☒
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        Delaware  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         0 shares  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING        

10,963,000

  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          0 shares  
    8   SHARED DISPOSITIVE POWER  
           
         

10,963,000

  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
       

10,963,000

  
  10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     ☐
       
           
  11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  
         
        7.8%  
  12  

TYPE OF REPORTING PERSON*

  
         
       

PN, IA 

  

 

9 

 

 

  1  

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY 

  
         
       

BVF Inc. 

  
  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) ☒
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        Delaware  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         0 shares  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING        

10,963,000

  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          0 shares  
    8   SHARED DISPOSITIVE POWER  
           
         

10,963,000

  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
       

10,963,000

  
  10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     ☐
       
           
  11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  
         
        7.8%  
  12  

TYPE OF REPORTING PERSON*

  
         
        CO  

 

10 

 

  

  1  

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY 

  
         
       

Mark N. Lampert 

  
  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) ☒
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
       

United States 

  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         0 shares  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING        

10,963,000

  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          0 shares  
    8   SHARED DISPOSITIVE POWER  
           
         

10,963,000

  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
       

10,963,000

  
  10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     ☐
       
           
  11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  
         
        7.8%  
  12  

TYPE OF REPORTING PERSON*

  
         
        IN  

 

11 

 

 

Item 1(a).Name of Issuer:

 

Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”).

 

Item 1(b).Address of Issuer’s Principal Executive Offices:

 

8800 Technology Forest Place

The Woodlands, Texas 77381

 

Item 2(a).Name of Person Filing

 

Item 2(b).Address of Principal Business Office or, if None, Residence

 

Item 2(c).Citizenship

 

Biotechnology Value Fund, L.P. (“BVF”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

 

BVF I GP LLC (“BVF GP”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

 

Biotechnology Value Fund II, L.P. (“BVF2”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

 

BVF II GP LLC (“BVF2 GP”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

 

Biotechnology Value Trading Fund OS LP (“Trading Fund OS”)

PO Box 309 Ugland House

Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

 

BVF Partners OS Ltd. (“Partners OS”)

PO Box 309 Ugland House

Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

 

BVF GP Holdings LLC (“BVF GPH”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

 

BVF Partners L.P. (“Partners”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

 

12 

 

 

BVF Inc.

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

 

Mark N. Lampert (“Mr. Lampert”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: United States

 

Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

 

Item 2(d).Title of Class of Securities:

 

Common Stock, par value $0.001 (the “Shares”).

 

Item 2(e).CUSIP Number:

 

528872302

 

Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

 

    ☒ Not applicable.
       
  (a) ☐ Broker or dealer registered under Section 15 of the Exchange Act.
       
  (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act.
       
  (c) ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act.
       
  (d) ☐ Investment company registered under Section 8 of the Investment Company Act.
       
  (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
       
  (f) ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
       
  (g) ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
       
  (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
       
  (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
       
  (j) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
       
  (k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

 

13 

 

 

Item 4.Ownership

 

(a)Amount beneficially owned:

 

As of the close of business on December 18, 2020, (i) BVF beneficially owned 5,791,837 Shares, (ii) BVF2 beneficially owned 4,255,514 Shares and (iii) Trading Fund OS beneficially owned 704,353 Shares.

 

BVF GP, as the general partner of BVF, may be deemed to beneficially own the 5,791,837 Shares beneficially owned by BVF.

 

BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 4,255,514 Shares beneficially owned by BVF2.

 

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 704,353 Shares beneficially owned by Trading Fund OS.

 

BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 10,047,351 Shares beneficially owned in the aggregate by BVF and BVF2.

 

Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 10,963,000 Shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and a certain Partners managed account (the “Partners Managed Account”), including 211,296 Shares held in the Partners Managed Account.

 

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 10,963,000 Shares beneficially owned by Partners.

 

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 10,963,000 Shares beneficially owned by BVF Inc.

 

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

 

(b)Percent of class:

 

The following percentages are based on 141,496,541 Shares outstanding, which is the total number of Shares outstanding as disclosed in the Issuer’s Prospectus filed pursuant to Rule 424(b)(5) of the Securities Act of 1933, as amended, with the Securities and Exchange Commission on December 11, 2020.

 

14 

 

 

As of the close of business on December 18, 2020, (i) BVF beneficially owned approximately 4.1% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 3.0% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 4.0% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 3.0% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 7.1% of the outstanding Shares and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 7.8% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).

 

(c)Number of shares as to which such person has:

 

(i)Sole power to vote or to direct the vote

 

See Cover Pages Items 5-9.

 

(ii)Shared power to vote or to direct the vote

 

See Cover Pages Items 5-9.

 

(iii)Sole power to dispose or to direct the disposition of

 

See Cover Pages Items 5-9.

 

(iv)Shared power to dispose or to direct the disposition of

 

See Cover Pages Items 5-9.

 

Item 5.Ownership of Five Percent or Less of a Class.

 

Not Applicable.

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF GPH.

 

Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not Applicable.

 

Item 8.Identification and Classification of Members of the Group.

 

See Exhibit 99.1.

 

Item 9.Notice of Dissolution of Group.

 

Not Applicable.

 

15 

 

 

Item 10.Certifications.

 

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

16 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Dated: December 21, 2020

 

BIOTECHNOLOGY VALUE FUND, L.P.   Biotechnology Value Trading Fund OS LP
     
By: BVF I GP LLC., its general partner      
      By: BVF Partners L.P., its investment manager
By: /s/ Mark N. Lampert   By: BVF Inc., its general partner
  Mark N. Lampert      
  Chief Executive Officer   By: /s/ Mark Lampert
        Mark Lampert
        President
BVF I GP LLC      
         
By: /s/ Mark N. Lampert   BVF GP HOLDINGS LLC
  Mark N. Lampert      
  Chief Executive Officer   By: /s/ Mark Lampert
        Mark Lampert
        Chief Executive Officer
BIOTECHNOLOGY VALUE FUND II, L.P.    
         
By: BVF II GP LLC, its general partner   BVF PARTNERS L.P.
         
By: /s/ Mark N. Lampert   By: BVF Inc., its general partner
  Mark N. Lampert      
  Chief Executive Officer   By: /s/ Mark N. Lampert
        Mark N. Lampert
        President
BVF II GP LLC      
         
By: /s/ Mark N. Lampert   BVF INC.
  Mark N. Lampert      
  Chief Executive Officer   By: /s/ Mark Lampert
        Mark Lampert
        President
BVF PARTNERS OS LTD.      
         
By: BVF Partners L.P., its sole member   /s/ Mark N. Lampert
By: BVF Inc., its general partner   MARK N. LAMPERT
         
By: /s/ Mark N. Lampert      
  Mark N. Lampert      
  President      

 

 

17